- Organizations: Thea Pharma, Inc.
Products
Thea Pharma's ZOLYMBUS ophthalmic gel launches for glaucoma management
The PF formulation debuts 9 months after securing FDA approval with a patented mucoadhesive lubricating gel technology for IOP reduction.
Products
FDA sends warning letters to three eye drop manufacturers
Agency identifies iVIZIA eye drops, Revitalize Energizing Eye Drops, and FOCUS PI Eye Drops as unapproved new drugs and misbranded products.
Products
Théa introduces new IYUZEH patient resources
New brochure and revamped website target patient-facing information and education—including a simplified process for prescription filling
Products
IYUZEH launches in the United States
Preservative-free formulation targets elevated IOP in OAG and OHT patients.
Research
Preservative Freedom Coalition is targeting ocular surface awareness
Launched by Théa Pharma, the organization advocates for improved patient outcomes and ensuring access to safe and effective preservative-free treatment options.
Products
Akorn Pharma recalls 70+ drugs from the US market
Company has ceased operations and shut down all facilities after filing for Chapter 7 bankruptcy in February 2023.
Research
Comparison study finds similar, positive profiles in Iyuzeh and Xalatan
Pivotal trial notes clinically meaningful reduction of IOP in Iyuzeh.
Products
Closing out 2022 with another FDA approval – Weekly Glance
The FDA has just approved Iyuzeh.
Pipeline